Vaccination against SARS-CoV-2 and risk of hospital admission and death among infected cancer patients: A population-based study in northern Italy

被引:6
作者
Gobbato, Michele [1 ,4 ]
Clagnan, Elena [1 ]
Toffolutti, Federica [2 ]
Del Zotto, Stefania [1 ]
Burba, Ivana [1 ]
Tosolini, Francesca [3 ]
Polimeni, Joseph [1 ]
Serraino, Diego [2 ]
Taborelli, Martina [2 ]
机构
[1] Agenzia Reg Coordinamento Salute, Udine, Italy
[2] IRCCS, Unit Canc Epidemiol, Ctr Riferimento Oncol Aviano CRO, Aviano, PN, Italy
[3] IRCCS, Direz Gen, Ctr Riferimento Oncol Aviano CRO, Aviano, PN, Italy
[4] ARCS Agenzia Reg Coordinamento Salute, Via Pozzuolo 330, I-33100 Udine, Italy
关键词
SARS-CoV-2; Vaccination; Cancer; Northeastern Italy; Hospital admission; Death; COVID-19; IMMUNOGENICITY;
D O I
10.1016/j.canep.2022.102318
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The risks of hospital admission for COVID-19-related conditions and all-cause death of SARS-CoV-2 infected cancer patients were investigated according to vaccination status.Methods: A population-based cohort study was carried out on 9754 infected cancer patients enrolled from January 1, 2021 to June 30, 2022. Subdistribution hazard ratio (SHRs) or hazard ratios (HRs) with 95 % confidence intervals (CI), adjusted for sex, age, comorbidity index, and time since cancer incidence, were computed to assess the risk of COVID-19 hospital admission or death of unvaccinated vs. patients with at least one dose of vaccine (i.e., vaccinated).Results: 2485 unvaccinated patients (25.5 %) were at a 2.57 elevated risk of hospital admission (95 % CI: 2.13-2.87) and at a 3.50 elevated risk of death (95 % CI: 3.19-3.85), as compared to vaccinated patients. Significantly elevated hospitalizations and death risks emerged for both sexes, across all age groups and time elapsed since cancer diagnosis. For unvaccinated patients, SHRs for hospitalization were particularly elevated in those with solid tumors (SHR = 2.69 vs. 1.66 in patients with hematologic tumors) while HRs for the risk of death were homogeneously distributed. As compared to boosted patients, SHRs for hospitalization and HRs for death increased with decreasing number of doses.Conclusions: Study findings stress the importance of SARS-CoV-2 vaccines to reduce hospital admission and death risk in cancer patients.
引用
收藏
页数:6
相关论文
共 21 条
[1]   Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer [J].
Addeo, Alfredo ;
Shah, Pankil K. ;
Bordry, Natacha ;
Hudson, Robert D. ;
Albracht, Brenna ;
Di Marco, Mariagrazia ;
Kaklamani, Virginia ;
Dietrich, Pierre-Yves ;
Taylor, Barbara S. ;
Simand, Pierre-Francois ;
Patel, Darpan ;
Wang, Jing ;
Labidi-Galy, Intidhar ;
Fertani, Sara ;
Leach, Robin J. ;
Sandoval, Jose ;
Mesa, Ruben ;
Lathrop, Kate ;
Mach, Nicolas ;
Shah, Dimpy P. .
CANCER CELL, 2021, 39 (08) :1091-+
[2]   Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors [J].
Barriere, J. ;
Chamorey, E. ;
Adjtoutah, Z. ;
Castelnau, O. ;
Mahamat, A. ;
Marco, S. ;
Petit, E. ;
Leysalle, A. ;
Raimondi, V. ;
Carles, M. .
ANNALS OF ONCOLOGY, 2021, 32 (08) :1053-1055
[3]   Acceptance of SARS-CoV-2 vaccination among French patients with cancer: a cross-sectional survey [J].
Barriere, J. ;
Gal, J. ;
Hoch, B. ;
Cassuto, O. ;
Leysalle, A. ;
Chamorey, E. ;
Borchiellini, D. .
ANNALS OF ONCOLOGY, 2021, 32 (05) :673-674
[4]   Immunogenicity and risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection after Coronavirus Disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis [J].
Becerril-Gaitan, Andrea ;
Vaca-Cartagena, Bryan F. ;
Ferrigno, Ana S. ;
Mesa-Chavez, Fernanda ;
Barrientos-Gutierrez, Tonatiuh ;
Tagliamento, Marco ;
Lambertini, Matteo ;
Villarreal-Garza, Cynthia .
EUROPEAN JOURNAL OF CANCER, 2022, 160 :243-260
[5]  
Calagnan E, 2020, EPIDEMIOL PREV, V44, P323, DOI 10.19191/EP20.5-6.S2.133
[6]   Seroconversion rate after vaccination against COVID-19 in patients with cancer-a systematic review [J].
Corti, C. ;
Antonarelli, G. ;
Scotte, F. ;
Spano, J. P. ;
Barriere, J. ;
Michot, J. M. ;
Andre, F. ;
Curigliano, G. .
ANNALS OF ONCOLOGY, 2022, 33 (02) :158-168
[7]  
COX DR, 1972, J R STAT SOC B, V34, P187
[8]   Comorbidity measures for use with administrative data [J].
Elixhauser, A ;
Steiner, C ;
Harris, DR ;
Coffey, RN .
MEDICAL CARE, 1998, 36 (01) :8-27
[9]   A proportional hazards model for the subdistribution of a competing risk [J].
Fine, JP ;
Gray, RJ .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1999, 94 (446) :496-509
[10]   COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study [J].
Garassino, Marina Chiara ;
Whisenant, Jennifer G. ;
Huang, Li-Ching ;
Trama, Annalisa ;
Torri, Valter ;
Agustoni, Francesco ;
Baena, Javier ;
Banna, Giuseppe ;
Berardi, Rossana ;
Bettini, Anna Cecilia ;
Bria, Emilio ;
Brighenti, Matteo ;
Cadranel, Jacques ;
De Toma, Alessandro ;
Chini, Claudio ;
Cortellini, Alessio ;
Felip, Enriqueta ;
Finocchiaro, Giovanna ;
Garrido, Pilar ;
Genova, Carlo ;
Giusti, Raffaele ;
Gregorc, Vanesa ;
Grossi, Francesco ;
Grosso, Federica ;
Intagliata, Salvatore ;
La Verde, Nicla ;
Liu, Stephen, V ;
Mazieres, Julien ;
Mercadante, Edoardo ;
Michielin, Olivier ;
Minuti, Gabriele ;
Moro-Sibilot, Denis ;
Pasello, Giulia ;
Passaro, Antonio ;
Scotti, Vieri ;
Solli, Piergiorgio ;
Stroppa, Elisa ;
Tiseo, Marcello ;
Viscardi, Giuseppe ;
Voltolini, Luca ;
Wu, Yi-Long ;
Zai, Silvia ;
Pancaldi, Vera ;
Dingemans, Anne-Marie ;
Van Meerbeeck, Jan ;
Barlesi, Fabrice ;
Wakelee, Heather ;
Peters, Solange ;
Horn, Leora .
LANCET ONCOLOGY, 2020, 21 (07) :914-922